IDEAYA Biosciences (IDEAYA Biosciences) Net Margin % : -865.76% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. IDEAYA Biosciences's Net Income for the three months ended in Dec. 2023 was $-33.96 Mil. IDEAYA Biosciences's Revenue for the three months ended in Dec. 2023 was $3.92 Mil. Therefore, IDEAYA Biosciences's net margin for the quarter that ended in Dec. 2023 was -865.76%.

The historical rank and industry rank for IDEAYA Biosciences's Net Margin % or its related term are showing as below:

IDYA' s Net Margin % Range Over the Past 10 Years
Min: -483.07 Med: -177.33 Max: -115.17
Current: -483.07

IDYA's Net Margin % is ranked worse than
65.34% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs IDYA: -483.07

IDEAYA Biosciences Net Margin % Historical Data

The historical data trend for IDEAYA Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Net Margin % Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-176.55

-178.10

-115.17

-483.05

IDEAYA Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-601.72	-300.00	-787.98	-341.38	-865.76

Competitive Comparison of IDEAYA Biosciences's Net Margin %

For the Biotechnology subindustry, IDEAYA Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Net Margin % falls into.

IDEAYA Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

IDEAYA Biosciences's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-112.961	/	23.385
	=	-483.05 %

IDEAYA Biosciences's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-33.955	/	3.922
	=	-865.76 %

IDEAYA Biosciences (NAS:IDYA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

IDEAYA Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

30J:Germany 30J:Germany

Address

7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Executives

Yujiro S Hata	director, officer: President and CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz	officer: See Remarks	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne	officer: VP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone	officer: SVP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre	officer: SVP, Chief Medical Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner	officer: SVP, Head of Biology	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner, Former 10% holder	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p.	10 percent owner, Former 10% holder	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107